Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models

Current Opinion in Pharmacology

Volumn 9, Issue 3, 2009, Pages 341-346

  Dupuis, Luc ^a,b   Loeffler, Jean Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; GABAPENTIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MINOCYCLINE; PENTOXIFYLLINE; PROTEIN NOGO A; RILUZOLE; SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTOSIS; DISEASE MODEL; ENERGY METABOLISM; HUMAN; HYPERLIPIDEMIA; HYPERMETABOLISM; LIPID METABOLISM; MUSCLE ATROPHY; MUSCLE DENERVATION; MUSCLE METABOLISM; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSGENICS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AXONS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUSCLE, SKELETAL; NEUROGLIA; NEUROMUSCULAR JUNCTION; SUPEROXIDE DISMUTASE;

EID: 65949094823     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.03.007     Document Type: Review

References (37)

1. Gros-Louis F., Gaspar C., and Rouleau G.A. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta 1762 (2006) 956-972
2. Boillee S., Vande Velde C., and Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52 (2006) 39-59
3. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
4. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
5. Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., and Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 92 (1995) 689-693
6. Jaarsma D., Haasdijk E.D., Grashorn J.A., Hawkins R., van Duijn W., Verspaget H.W., London J., and Holstege J.C. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol Dis 7 (2000) 623-643
7. Gonzalez de Aguilar J.L., Echaniz-Laguna A., Fergani A., Rene F., Meininger V., Loeffler J.P., and Dupuis L. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem 101 (2007) 1153-1160
8. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., and Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185 (2004) 232-240
9. Guegan C., and Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 111 (2003) 153-161
10. ••].
11. ••].
12. ••], shows that the complete rescue of motor neuron cell bodies is not sufficient to delay significantly the pathology, strongly suggesting that NMJ destruction is the pathogenic event.
13. Lino M.M., Schneider C., and Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 22 (2002) 4825-4832
14. Pramatarova A., Laganiere J., Roussel J., Brisebois K., and Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 21 (2001) 3369-3374
15. Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., and Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci 28 (2008) 2075-2088
16. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., and Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
17. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003) 113-117
18. •].
19. •].
20. •] demonstrate that astrocytes expressing mutant SOD1 are able to secrete toxic factors selectively toxic for motor neurons.
21. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., and Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11 (2008) 251-253. This work is the first in vivo demonstration of an active role of astrocytic mSOD1 expression in mSOD1-mediated pathogenesis.
22. Beers D.R., Henkel J.S., Xiao Q., Zhao W., Wang J., Yen A.A., Siklos L., McKercher S.R., and Appel S.H. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 103 (2006) 16021-16026
23. Towne C., Raoul C., Schneider B.L., and Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 16 (2008) 1018-1025. The authors describe that knocking down mSOD1 in multiple tissues, including muscles, does not modify the pathogenesis, suggesting that decreasing mSOD1 expression in muscle might not be a valuable therapeutic strategy.
24. Miller T.M., Kim S.H., Yamanaka K., Hester M., Umapathi P., Arnson H., Rizo L., Mendell J.R., Gage F.H., Cleveland D.W., et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 103 (2006) 19546-19551
25. Jokic N., Gonzalez de Aguilar J.L., Pradat P.F., Dupuis L., Echaniz-Laguna A., Muller A., Dubourg O., Seilhean D., Hauw J.J., Loeffler J.P., et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 57 (2005) 553-556
26. Dupuis L., Gonzalez de Aguilar J.L., di Scala F., Rene F., de Tapia M., Pradat P.F., Lacomblez L., Seihlan D., Prinjha R., Walsh F.S., et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 10 (2002) 358-365
27. Pradat P.F., Bruneteau G., Gonzalez de Aguilar J.L., Dupuis L., Jokic N., Salachas F., Le Forestier N., Echaniz-Laguna A., Dubourg O., Hauw J.J., et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 62 (2007) 15-20
28. Jokic N., Gonzalez de Aguilar J.L., Dimou L., Lin S., Fergani A., Ruegg M.A., Schwab M.E., Dupuis L., and Loeffler J.P. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 7 (2006) 1162-1167
29. Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., and Musaro A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168 (2005) 193-199
30. Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Bonconpagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 8 (2008) 425-436. This is the first demonstration of an active role of skeletal muscle mSOD1 expression in mSOD1-mediated pathogenesis.
31. Dupuis L., Oudart H., Rene F., Gonzalez de Aguilar J.L., and Loeffler J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A 101 (2004) 11159-11164
32. Mattson M.P., Cutler R.G., and Camandola S. Energy intake and amyotrophic lateral sclerosis. Neuromol Med 9 (2007) 17-20
33. Fergani A., Oudart H., Gonzalez De Aguilar J.L., Fricker B., Rene F., Hocquette J.F., Meininger V., Dupuis L., and Loeffler J.P. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res 48 (2007) 1571-1580
34. Dupuis L., Corcia P., Fergani A., Gonzalez De Aguilar J.L., Bonnefont-Roussel D., Bittar R., Seilhean D., Hauw J.J., Lacomblez L., Loeffler J.P., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70 (2008) 1004-1009. This paper describes systemic alterations of lipidemia in ALS patients and their correlation with survival.
35. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26 (2007) 1-13
36. Scott S., Kranz J.E., Cole J., Lincecum J.M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B.M., Vieira F.G., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9 (2008) 4-15. The authors failed to replicate a number of published positive effects in mSOD1 mice and conclude that most of these effects are experimental noise.
37. Ludolph A.C., Bendotti C., Blaugrund E., Hengerer B., Loffler J.P., Martin J., Meininger V., Meyer T., Moussaoui S., Robberecht W., et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler 8 (2007) 217-223. This consortium of ALS researchers set up guidelines in establishing rigorous preclinical trials in mSOD1 mice.